Tonghua Dongbao: Liraglutide Injection Obtained Drug Registration Certificate in Nicaragua.

Tonghua Dongbao announced that the company recently received the drug registration certificate for Liraglutide injection approved and issued by the National Health Regulatory Authority of Nicaragua. Liraglutide injection is 18 mg/3ml and is indicated for diabetes. It is produced by Tonghua Dongbao Pharmaceutical Co., Ltd., with production address in Dongbao New Village, Tonghua County, Jilin Province. Nicaragua is the largest country in Central America, with a total population of approximately 7.07 million in 2025. The diabetes prevalence rate among adults aged 20-79 is 8.7%, and the average annual diabetes-related expenditure per patient is $587. There is an urgent demand for high-quality, affordable treatments for diabetes and metabolic diseases.